Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

证券日报网讯1月6日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东数为18111户。 ...

责任编辑：小浪快报 第2笔成交价格为18.07元，成交77.00万股，成交金额1,391.39万元，溢价率为-1.69%，买方营业部为中 国中金财富证券有限公司上海黄浦区湖滨路证券营业部，卖方营业部为西南证券股份有限公司湖南分公 司。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为3035.76万元。该股近5个交易日累 计上涨1.94%，主力资金合计净流出566.03万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月31日，易明医药收涨1.72%，收盘价为18.38元，发生2笔大宗交易，合计成交量168万股，成交金额 3035.76万元。 第1笔成交价格为18.07元，成交91.00万股，成交金额1,644.37万元，溢价率为-1.69%，买方营业部为华 林证券股份有限公司深圳分公司，卖方营业部为西南证券股份有限公司湖南分公司。 ...

证券日报网讯12月24日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月19 日，公司股东数为18066户。 ...

Group 1 - The core point of the article is that Yiming Pharmaceutical has responded to investor inquiries, indicating that as of November 20, 2025, the number of shareholders will be 18,924 [2]

Core Insights - Yiming Pharmaceutical stated that as of October 31, 2025, the number of shareholders will be 21,147 [2] Company Summary - Yiming Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is projecting a specific number of shareholders for a future date, indicating a focus on shareholder engagement and growth [2]

Core Insights - 易明医药 is a pharmaceutical company established in December 2007, focusing on the research, production, and sales of chemical drugs and traditional Chinese medicine, with strengths in generic drugs [1] Financial Performance - In Q3 2025, 易明医药 reported revenue of 489 million yuan, ranking 81st among 110 companies in the industry, while the industry leader, 华东医药, achieved revenue of 32.664 billion yuan [2] - The company's net profit for the same period was 81.76 million yuan, placing it 55th in the industry, with the top performer, 恒瑞医药, reporting a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, 易明医药's debt-to-asset ratio was 24.24%, an increase from 22.52% year-on-year, which is below the industry average of 35.26% [3] - The company's gross profit margin for Q3 2025 was 82.15%, up from 67.05% year-on-year, exceeding the industry average of 57.17% [3] Management Compensation - The total compensation for the general manager was 681,600 yuan in 2024, a decrease of 23,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 19,400, while the average number of circulating A-shares held per shareholder increased by 9.38% to 8,968.79 [5]

Core Insights - Yiming Pharmaceutical (002826.SZ) reported its Q3 2025 results, highlighting significant institutional investment growth [1] Institutional Holdings - As of October 28, 2025, five institutional investors disclosed holdings in Yiming Pharmaceutical, totaling 48.1693 million shares, which represents 25.26% of the company's total share capital [1] - The institutional holding percentage increased by 24.33 percentage points compared to the previous quarter [1] Public Fund Activity - One new public fund disclosed its holdings this quarter, namely Wanji Zhongzheng 2000 Index Enhanced A [1] - Eleven public funds were not disclosed in this quarter compared to the previous one, including notable funds such as CITIC Securities Quantitative Selection A and Jianxin Zhongzheng 500 Index Enhanced A [1]

Core Viewpoint - The company, Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2]. Financial Data Summary - The company reported a 30.35% decrease in cash and cash equivalents compared to the beginning of the period, primarily due to investments in financial products [5]. - Trading financial assets increased by 280 million yuan, attributed to the purchase of short-term financial products [5]. - Accounts receivable notes decreased by 94.26%, reflecting the maturity and settlement of receivables [5]. - Prepayments increased by 3.75 million yuan, mainly due to payments made to suppliers and for engineering projects [5]. - Construction in progress doubled compared to the beginning of the period, due to payments for production line renovations [5]. - Accounts payable grew by 34.33%, linked to increased procurement and promotional service fees [5]. - Contract liabilities decreased by 57.03%, indicating a reduction in advance payments received [5]. - Tax liabilities increased by 13.06 million yuan, reflecting higher corporate income tax and VAT provisions [5]. - Other payables rose by 90.17%, primarily due to the recognition of obligations related to a stock incentive plan [5]. - Operating costs decreased by 48.35% year-on-year, due to the termination of third-party product collaborations [5]. - Financial expenses increased by 78.55%, driven by higher interest expenses from increased short-term borrowings [5]. - Investment income rose by 803,100 yuan, attributed to increased returns from financial product investments [5]. - Net cash flow from operating activities grew by 31.41%, due to increased sales and government subsidies [5]. Shareholder Information - As of the reporting period, the company’s shares held by the repurchase account amounted to 3,403,800 shares, representing 1.79% of the total share capital [7]. - A significant change in control occurred when Beijing Fuhai Enterprise Management Partnership acquired 23.00% of the company's shares from the previous controlling shareholder [7][8]. Board Meeting and Governance - The fourth board meeting was held on October 27, 2025, with all directors present, and the meeting complied with relevant laws and regulations [10][11]. - The board approved the third-quarter report, confirming that it accurately reflects the company's situation without any misleading statements [11][12].

Major Events - *ST Zhengping's stock will be suspended for investigation starting October 29, 2025, due to a significant price increase of 152.42% from September 1 to October 28, 2025, with 21 days of trading halts and 5 instances of abnormal trading fluctuations [2] - Gongjin Co. announced that its major shareholder is planning a share transfer that may lead to a change in control, resulting in the stock being suspended from October 27, 2025, for up to 3 trading days [2] - Jiuquan Technology's wholly-owned subsidiary plans to invest 150 million yuan in establishing an industrial fund focused on chips and integrated circuits [2] Company Announcements - YN Holdings decided to terminate investment in 17 distributed photovoltaic projects originally planned for a total investment of 1.197 billion yuan due to changes in market conditions [3] - Awan New Materials announced a one-day stock suspension on October 29, 2025, due to a tender offer from Shanghai Zhiyuan Hengyue Technology Partnership, aiming to acquire 149,243,840 shares at 7.78 yuan per share [4] - Dahua Intelligent clarified that it currently has no business related to quantum technology despite market speculation [5] Financial Performance - Ganfeng Lithium reported a net profit of 557 million yuan for Q3 2025, a year-on-year increase of 364.02%, with revenues of 6.249 billion yuan, up 44.10% [6] - Light Media's net profit for Q3 2025 reached 1.06 billion yuan, a 993.71% increase, with revenues of 374 million yuan, up 247.54% [6] - Hainan Airport reported a net profit of 64.35 million yuan for the first three quarters of 2025, a decline of 69.77% [7] - Su Li Co. achieved a net profit of 59.42 million yuan in Q3 2025, a 2750% increase, with revenues of 762 million yuan, up 26% [7] - Yutong Bus reported a net profit of 1.357 billion yuan for Q3 2025, a 78.98% increase, with revenues of 10.237 billion yuan, up 32.27% [9] Share Buybacks - Haida Group plans to repurchase shares worth between 1 billion to 1.6 billion yuan for capital reduction and employee stock ownership plans, with a maximum price of 62 yuan per share [20] - Liyuan Information intends to repurchase shares totaling 20 million to 30 million yuan, with a maximum price of 15 yuan per share [21] Major Contracts - Baiao Intelligent won a project worth 97.22 million yuan from a large state-owned company [22] - Guangdong Construction signed a construction contract worth 1.924 billion yuan for a project in Guangzhou, which will enhance its business scale and profitability [22] - Guangqi Technology's subsidiary signed contracts for mass production of metamaterials worth a total of 215 million yuan [23]